Top Gene Editing Startups of July 2023

Gene editing technology has emerged as a groundbreaking tool in the field of genetic medicine, offering unprecedented opportunities to treat and potentially cure genetic diseases. With the ability to precisely modify DNA sequences, gene editing startups are at the forefront of revolutionizing healthcare and personalized medicine.

In this article, we delve into the world of gene editing startups, uncovering the innovative companies that are harnessing the power of CRISPR and other gene editing technologies to unlock the future of genetic medicine.

These cutting-edge startups are driven by a common goal: to advance the frontiers of medical science and improve the lives of millions affected by genetic disorders. By harnessing the potential of gene editing, these pioneers are developing groundbreaking therapies, creating hope for patients and their families.

Join us as we explore the top gene editing startups that are rewriting the code of medicine, one gene at a time.

Top Gene Editing Startups of July 2023

CRISPR Therapeutics

CRISPR Therapeutics

CRISPR Therapeutics is based in Zug, Switzerland; however, they also have operations in the United States, specifically in Cambridge, Massachusetts. This innovative company was founded in 2013. While the exact amount raised by the company can vary over time based on different funding rounds and market activities, as of the last count, CRISPR Therapeutics had raised approximately $289 million in funding.

CRISPR Therapeutics is a leading gene editing company that uses a tool known as the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system. This system enables them to perform targeted modifications to the genome of living organisms. The company’s goal is to develop transformative gene-based medicines for serious human diseases. CRISPR Therapeutics currently has several therapies in clinical trials, including treatments for sickle cell disease, beta-thalassemia, and various types of cancer.


Intellia Therapeutics

Intellia Therapeutics is an American biotechnology company that was founded in 2014. The company is based in Cambridge, Massachusetts.

As per the available data until now, Intellia has raised approximately $361.3M in total funding.

Intellia Therapeutics is dedicated to developing potentially curative gene editing treatments by levering CRISPR/ cas9 technology. The company’s pipeline is focused on curing severe diseases by editing the cells in the body with a pragmatic focus on primary liver diseases. Their approach focuses on harnessing the body’s natural repair mechanisms to achieve therapeutic benefit.


Editas Medicine

Editas Medicine is a startup company located in Cambridge, Massachusetts, USA. The company was founded in 2013. As of today, the company has raised approximately $267.2 million in funding over a span of 6 rounds.

Editas Medicine is a leading genome editing company with a mission to translate the power and potential of CRISPR-Cas9 gene editing technologies into a robust pipeline of treatments for people living with serious diseases. The company’s focus is on using its editing capabilities to cure diseases at the genetic level by effectively deleting harmful genes and inserting beneficial ones. It has major developments in treating eye diseases, cancer, blood disorders, and many rare diseases.

Beam Therapeutics

Beam Therapeutics

Beam Therapeutics is a biotechnology company that is located in Cambridge, Massachusetts, USA. It was founded in the year 2017.

According to the available data till now, Beam Therapeutics has raised a total of $222 million in funding. However, it’s important to note that funding amounts can change frequently as startups often go through multiple rounds of financing.

As for the description of the company: Beam Therapeutics is pioneering the use of base-editing technologies to develop precision genetic medicines for patients suffering from serious diseases. The company’s innovative approach allows it to make single base changes to DNA or RNA, creating the potential for transformative therapies that can correct or modify the underlying cause of a range of genetic diseases. Beam Therapeutics is recognized for its unique approach to gene editing that sets it apart from traditional CRISPR-Cas9 methods. Their proprietary base editing technology has the potential to provide life-changing treatments for patients with unmet medical needs.

Verve Therapeutics

Verve Therapeutics

Verve Therapeutics is a biotechnology company located in Cambridge, Massachusetts, United States. It was founded in the year 2016. As of my last update, the company has raised approximately $123.5 million in funding.

Verve Therapeutics is committed to protecting the world from heart disease. The company uses a single-course gene editing medicine to permanently treat cardiovascular disease. Their therapies are intended to mimic naturally occurring protective genetic mutations to prevent the disease occurring for the entirety of a person’s life after one-time use. Verve’s initial focus is on developing treatments for adults with coronary artery disease, the most common form of heart disease.

Twist Bioscience

Twist Bioscience

Twist Bioscience is an innovative company located in San Francisco, California, USA. The company was founded in 2013 by Emily Leproust, Bill Peck, and Bill Banyai.

As per the latest available information, Twist Bioscience has raised around $703 million in funding rounds. This data is subject to change as startups frequently participate in additional rounds of financing.

On the descriptive part, Twist Bioscience is a pioneer in the field of synthetic biology. The company’s main focus is the manufacture of synthetic DNA for clients in the fields of healthcare, agriculture, industrial chemicals, and data storage. Utilizing a high-throughput silicon platform, Twist Bioscience is able to generate synthetic biology tools, including genes, oligonucleotide pools, and variant libraries. These tools are subsequently used in therapeutic discovery and agricultural biotech industries, among others. Twist Bioscience fundamentally aims to improve human health and sustainability through its innovative practices in genomics and synthetic biology.

GenScript Biotech Corp


GenScript Biotech Corp is located in Nanjing, China. The company was founded in the year 2002. Information about the exact amount the company has raised is not readily available. However, it’s crucial to note that as a publicly traded company on the Hong Kong Stock Exchange, its financial status is subject to fluctuation based on stock performance and investor decisions.

As for a description, GenScript Biotech Corp is a global biotechnology group. It is deeply dedicated to empowering life science research, transforming biopharmaceutical drug discovery, and expanding human health. With its diverse portfolio of capabilities including gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, and in vitro and in vivo pharmacology, GenScript aims to enable advancements in life sciences and translational medicine.

Frequently Asked Questions

1. What is gene editing, and how does it work?

Gene editing is a revolutionary technology that allows scientists to make precise changes to the DNA sequence of living organisms. Using specialized enzymes like CRISPR-Cas9, gene editing startups can add, delete, or modify specific genes, potentially correcting genetic mutations that cause diseases.

2. How are gene editing startups contributing to advancements in genetic medicine?

Gene editing startups are pioneering new therapeutic approaches to treat genetic disorders. By targeting disease-causing genetic mutations, these startups aim to develop transformative gene therapies, gene replacements, and gene corrections that hold the promise of curing previously untreatable conditions.

3. What are some of the key gene editing technologies utilized by these startups?

The most prominent gene editing technology utilized by startups is CRISPR-Cas9, known for its simplicity and versatility. Additionally, other gene editing tools like zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) are also being explored for specific applications.

4. What are some of the genetic diseases targeted by gene editing startups?

Gene editing startups are targeting a wide range of genetic diseases, including rare genetic disorders like cystic fibrosis and sickle cell anemia, as well as more prevalent conditions like muscular dystrophy and certain types of cancer.

5. What are the potential challenges and ethical considerations associated with gene editing?

While gene editing holds tremendous promise, there are ethical considerations regarding the potential misuse of this technology, the need for informed consent in human trials, and the long-term effects of altering human DNA. Regulatory bodies closely monitor gene editing to ensure responsible and ethical use.

6. How do gene editing startups ensure the safety and efficacy of their therapies?

Gene editing startups conduct rigorous preclinical studies and adhere to strict regulatory standards to ensure the safety and efficacy of their therapies. These startups collaborate with regulatory agencies to design robust clinical trials that assess the therapy’s benefits and potential risks.

7. How do gene editing startups secure funding for their research and development?

Gene editing startups secure funding through a variety of means, including venture capital investments, partnerships with pharmaceutical companies, government grants, and collaborations with research institutions.

8. What are some of the recent breakthroughs and achievements of gene editing startups?

Recent breakthroughs include successful clinical trials of gene therapies for genetic diseases like spinal muscular atrophy (SMA) and beta-thalassemia, with some therapies gaining regulatory approvals for commercialization.

9. How do gene editing startups approach personalized medicine and patient-specific treatments?

Gene editing startups aim to develop personalized therapies tailored to an individual’s genetic makeup, offering the potential for more effective and precise treatments. By targeting specific genetic mutations unique to each patient, gene editing enables personalized medicine to address the diverse needs of patients.

10. How are gene editing startups shaping the future of healthcare?

Gene editing startups are transforming the landscape of healthcare by offering the possibility of cures for once-incurable genetic diseases. As these startups continue to make strides in research and development, the future of medicine looks increasingly promising and patient-centric.

11. What is the regulatory landscape for gene editing therapies?

The regulatory landscape for gene editing therapies varies by country and region. Regulatory bodies such as the FDA in the United States and the EMA in Europe carefully assess the safety and efficacy of gene editing therapies before granting approvals for clinical use.

12. How can individuals and the broader society support gene editing research and innovation?

Support for gene editing startups can be facilitated through public awareness and education about the potential benefits of genetic medicine. Additionally, supporting policy initiatives that foster responsible gene editing research and patient access to transformative therapies can also play a significant role.

Check out the top insurtech startups of 2023